Protein Expression of PTTG1 as a Diagnostic Biomarker in Adrenocortical Carcinoma

[1]  R. Heshmat,et al.  Corrigendum: Expression of the Pituitary Tumor Transforming Gene (PTTG1) in Pheochromocytoma as a Potential Marker for Distinguishing Benign Versus Malignant Tumors. , 2015, Acta medica Iranica.

[2]  S. Ni,et al.  Pituitary tumor-transforming gene-1 serves as an independent prognostic biomarker for gastric cancer , 2015, Gastric Cancer.

[3]  G. Scagliotti,et al.  MicroRNA expression patterns in adrenocortical carcinoma variants and clinical pathologic correlations. , 2014, Human pathology.

[4]  P Kronqvist,et al.  Cdc20 and securin overexpression predict short-term breast cancer survival , 2014, British Journal of Cancer.

[5]  D. Zheng,et al.  Overexpression of pituitary tumor transforming gene (PTTG) is associated with tumor progression and poor prognosis in patients with esophageal squamous cell carcinoma. , 2014, Acta histochemica.

[6]  S. Jolly,et al.  Adrenocortical Carcinoma , 2010, Cancers.

[7]  Elizabeth Stephan,et al.  PTTG1 overexpression in adrenocortical cancer is associated with poor survival and represents a potential therapeutic target. , 2013, Surgery.

[8]  C. Der,et al.  CRL4A-FBXW5–mediated degradation of DLC1 Rho GTPase-activating protein tumor suppressor promotes non-small cell lung cancer cell growth , 2013, Proceedings of the National Academy of Sciences.

[9]  Jui‐I Chao,et al.  Evidence of securin-mediated resistance to gefitinib-induced apoptosis in human cancer cells. , 2013, Chemico-biological interactions.

[10]  B. Scheithauer,et al.  Immunohistochemical expression of PTTG in brain tumors , 2008, Anticancer research.

[11]  C. Schade-Brittinger,et al.  Combination chemotherapy in advanced adrenocortical carcinoma. , 2012, The New England journal of medicine.

[12]  Wei Zhang,et al.  The use of a combination of Ki-67, Galectin-3, and PTTG can distinguish the benign and malignant thyroid tumor. , 2012, Clinical laboratory.

[13]  Pei-Ming Yang,et al.  Securin depletion sensitizes human colon cancer cells to fisetin-induced apoptosis. , 2011, Cancer letters.

[14]  L. Weiss,et al.  The Weiss system for evaluating adrenocortical neoplasms: 25 years later. , 2009, Human pathology.

[15]  Paul G. Gauger,et al.  Molecular Classification and Prognostication of Adrenocortical Tumors by Transcriptome Profiling , 2009, Clinical Cancer Research.

[16]  D. Schteingart.  Adrenocortical Carcinoma in the United States: Treatment Utilization and Prognostic Factors , 2009 .

[17]  D. Rubello,et al.  Adrenal tumors. , 2009, Minerva endocrinologica.

[18]  Jeffrey E. Lee,et al.  Recurrence of Adrenal Cortical Carcinoma Following Resection: Surgery Alone Can Achieve Results Equal to Surgery Plus Mitotane , 2009, Annals of Surgical Oncology.

[19]  T. Abe,et al.  Immunohistochemistry of a proliferation marker Ki67/MIB1 in adrenocortical carcinomas: Ki67/MIB1 labeling index is a predictor for recurrence of adrenocortical carcinomas. , 2008, Endocrine journal.

[20]  S. Melmed,et al.  Pituitary tumor-transforming gene: physiology and implications for tumorigenesis. , 2007, Endocrine reviews.

[21]  M. Malumbres,et al.  A census of mitotic cancer genes: new insights into tumor cell biology and cancer therapy. , 2006, Carcinogenesis.

[22]  Martin Fassnacht,et al.  Adrenocortical Carcinoma: Clinical Update , 2006 .

[23]  N. Chattopadhyay,et al.  The emerging role of pituitary tumor transforming gene in tumorigenesis. , 2006, Clinical medicine & research.

[24]  P. Devos,et al.  Weiss System Revisited: A Clinicopathologic and Immunohistochemical Study of 49 Adrenocortical Tumors , 2002, The American journal of surgical pathology.

[25]  M. Kirschner,et al.  Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. , 1999, Science.

[26]  L. Medeiros,et al.  Cellular DNA Profiles of Benign and Malignant Adrenocortical Tumors , 1990, The American journal of surgical pathology.